Andere Sprachen WPD Pharmaceuticals Inc.

Aktien

A2PX9R

CA92941F1053

WBIO

Markt geschlossen - Canadian Securities Exchange Andere Börsenplätze 15:49:31 28.06.2022			% 5 Tage	% 1. Jan.
0,045 ^CAD	-.--%		-.--%	-.--%

05.02.	WPD Pharmaceuticals Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI
02.02.	WPD Pharmaceuticals Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	05.02.
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02.02.
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30.01.
WPD Pharmaceuticals : Sp. z o. o., received the second tranche of the funds	02.11.
WPD Pharmaceuticals : Sp. z o. o., received the first tranche of the funds	08.09.23
WPD Pharmaceuticals : Polish Subsidiary Signs Investment Agreement with ACRX Investments Limited	01.09.23
WPD Pharmaceuticals : Announces Closing of Convertible Debenture Private Placement	16.06.23
WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in funding	15.06.23
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline	02.05.23
WPD Pharmaceuticals Inc. Announces Directorate Appointments	02.05.23
WPD Pharmaceuticals Inc. announced that it expects to receive CAD 0.3 million in funding	01.05.23
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy	18.01.23
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)	19.12.22
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin	05.12.22
Liam Corcoran Resigns from WPD Pharmaceuticals Inc.'s Board of Directors, Effective December 1, 2022	25.11.22
WPD Pharmaceuticals : Provides a Corporate Update	18.11.22
WPD Pharmaceuticals Inc. announced that it expects to receive PLN 1.7 million in funding	14.09.22
IIROC Trading Halt - WBIO	11.07.22
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	16.05.22
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	16.05.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen WPD Pharmaceuticals Inc.

Aktien

A2PX9R

CA92941F1053

WBIO

Andere Sprachen

Filter